PHAR News

European Commission grants marketing authorization to Pharming’s Joenja® (leniolisib) – the first approved treatment for APDS in the European Union

Pharming Group announces presentations at CIS 2026 Annual Meeting, including leniolisib pediatric data in APDS and clinical experience in CVID and related disorders

Pharming Group reports first quarter 2026 financial results; on track for Joenja® U.S. pediatric label expansion and launches in Japan and Europe in 2026

Pharming Group to report first quarter 2026 financial results and provide business update on May 7

Pharming Group announces the 2026 Annual General Meeting of Shareholders

Pharming Group N.V. Investigated by the Portnoy Law Firm

Pharming Group to participate in April investor conferences

Pharming Group announces the filing of its 2025 Annual Report and Form 20-F

Pharming Group receives positive CHMP opinion for Joenja® (leniolisib) for the treatment of APDS in adult and pediatric patients 12 years and older

Pharming Group announces approval of Joenja® (leniolisib) in Japan for the treatment of APDS in patients aged 4 years and older